肺癌术后行肺动脉灌注化疗的探讨

目的：比较肺动脉灌注化疗与外周静脉化疗用于中、晚期肺癌肺叶切除术后的远期疗效。方法：90年例患者随机分为2组。PAI组于肺叶切除后行选择性肺动脉灌注化疗；Ⅵ组则于手术后行外周静脉化疗。结果：PAI组共化疗215疗程，平均4．8疗程；VI组化疗195疗程，平均4．3疗程。PAI组1、3、5年生存率分别为88．9％、77．8％和47．4％，VI组则为82．2％，53．3％和20．5％，两组间3、5年生存率比较有显著差异（P＜0．05）。PAI组根治手术病例3年局部复发率为12．8％，VI组为35．0％（P＜0．05）。PAI组1、3、5RH TLD TF LFTQTJT V YX O 17．8％、20．0％和26．3％，VI组为15．6％，35．6％和51．3％，两组间3、5年血行转移复发率有显著性差异（P＜0．05）。结论：选择性肺动脉灌注化疗用于肺叶切除后的肺癌患者，能够杀灭和抑制局部微转移灶，减少局部复发和远期血行转移的发生率，提高长期生存率。

Study on pulmonary artery infusion following lobectomy in patients with lung cancer

Objective To evaluate the efficacy of pulmonary artery infusion (PAI) via post catheter connecting system in patients with lung cancer after lobectomy. Methods Ninety patients were randomized into two groups after lobectomy and each group had 45 patients. The PAI group received chemotherapy via pulmonary artery, while the VI group received chemotherapy via peripheral vein. Results The PAI group totally received 215 cycles of chemotherapy, 4.8 cycles in average. The VI group received 195 cycles, 4.3 cycles in average. The 1 , 3 , 5 year survival rates in PAI group were 88.9%, 77.8%, 47.4% respectively, and 82.2%, 53.3%, 20.5% in VI group. And there were significant differences in the 3 and 5 year survival rates between the two groups (P<0.05). The 3 year local recurrence rate was 12.8% for radical lobectomy patients in PAI group, and 35.0% in VI group (P<0.05). The 1 , 3 , 5 year metastatic rates after lobectomy were 17.8%, 20.0%, 26.3% respectively in PAI group, and 15.6%, 35.6%, 51.3% respectively in VI group. And there were significant differences in the 3 and 5 year metastatic rates between the two groups (P<0.05). Conclusion Pulmonary artery infusion for lung cancer patients after lobectomy can reduce the post operative recurrence and metastasis and improve the long term survival rates.